Cite
MLA Citation
Dirk Müller et al.. “Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.” Leukemia & lymphoma, vol. 57, no. 5, n.d., pp. 1130–1139. http://access.bl.uk/ark:/81055/vdc_100034281744.0x000056